Portal about health, medical articles.

Access Pharmaceuticals Provides Update On ProLindac(TM) Phase 2 Ovarian Cancer Trial And Clinical Development Plan

ACCESS PHARMACEUTICALS, INC.(OTC Bulletin Board: ACCP), provided an update on the progress in the Company"s clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies. Access recently announced positive safety and efficacy results from its Phase 2 monotherapy clinical study of ProLindac(TM) in late-stage, heavily pretreated ovarian cancer patients. In this study, 66% of patients who received the highest dose achieved clinically meaningful disease stabilization according to RECIST criteria. No patient in any dose group exhibited any signs of acute neurotoxicity, which is a major adverse side-effect of the approved DACH platinum, Eloxatin, and ProLindac was well tolerated overall. The Company has scaled up manufacturing in order to begin the next phase of clinical development. Access plans to conduct several combination trials in different solid tumor types both as Company-sponsored trials and in conjunction with its two previously announced co-development partners.
generic viagra online

Physicians Caught In Bureaucratic Nightmare While Medicaid Children Suffer, USA

While only two-thirds of Texas doctors treat Medicaid patients, a Texas government agency is using tactics that might turn more doctors away from the program, according to the Texas Medical Association (TMA).

News of the day

For Most Late-Stage Colorectal Cancers Surgery Is Not Necessary

A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don"t require immediate surgery to remove the primary tumor in the colon. Researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) presented their data at the American Society of Clinical Oncology Annual Meeting.